Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 20/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25723757 | 0.94 | CHRM5 (0.75) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL30456479 | 0.91 | CHRM5 (0.70) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25232315 | 0.87 | CHRM5 (0.77) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25723758 | 0.86 | CHRM5 (0.73) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL30456902 | 0.85 | CHRM5 (0.75) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25233803 | 0.85 | CHRM5 (0.75) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25276193 | 0.83 | CHRM5 (1.00) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL30456734 | 0.83 | CHRM5 (0.87) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25230590 | 0.82 | CHRM5 (0.70) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 | |
| SCHEMBL25423103 | 0.82 | CHRM5 (0.79) | CHRM5CYP3A4CYP2D6CHRM1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | CHRM5 1/4885CYP3A4 520/4885CYP2D6 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.